Jim Cramer Labels Moderna A 'Big Disappointment,' But Suggests Doubling Down On Another Pharma Powerhouse
Jim Cramer likes Pfizer and recommends buying more stock. Six Flags is struggling, but Cramer likes First Solar and Equity ...
Down More Than 50%, Is It Time to Buy Moderna Stock as the Biotech Charts a New Post-COVID Path?
With the stock now more than cut in half from its 52-week high, the company recently laid out a plan for its business at its ...
The Motley Fool6d
Down More Than 50%, Is It Time to Buy Moderna Stock as the Biotech Charts a New Post-COVID Path?
The first was to increase the usage of its Spikevax and mRESVIA ... launches in new markets in 2025. Moderna is also expecting to get approval to expand the label to high-risk people under the ...
BioSpace8d
Facing ‘Daunting’ Launch Schedule, Moderna to Slash $4B in R&D Spend by 2028
Analysts expressed skepticism about plans detailed by Moderna’s R&D chief Stephen Hoge to trim research spending in ...
Joplin Globe9d
Moderna R&D Day Highlights Progress and Strategic Priorities
Expects to submit next-generation COVID vaccine for approval in 2024 Expects to submit flu/COVID combination vaccine for approval in 2024 Announces positive Phase 3 results for its RSV vaccine for ...
The Victoria Advocate10d
Moderna R&D Day Highlights Progress and Strategic Priorities
Specifically, in 2021-2023, Moderna invested proceeds from its pandemic-era vaccine sales into building a diverse pipeline and established the market for its COVID-19 vaccine, Spikevax®.